1-4 of 4
Ruo-Jing Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Ashley Woods, Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin Chiu Yuen Chow, Ruo-Jing Li, Jielin Sun, Rosane Charlab, Xiling Jiang, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1226–1231.
https://doi.org/10.1158/1078-0432.CCR-23-2234
Published: 01 April 2024
View article titled, FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an <em>IDH1</em> Mutation
Open the PDF for FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an <em>IDH1</em> Mutation in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Donna Przepiorka, Robert Q. Le, Alexei Ionan, Ruo-Jing Li, Ying-Hong Wang, Ramadevi Gudi, Soumya Mitra, Jonathon Vallejo, Olanrewaju O. Okusanya, Lian Ma, Yuching Yang, Paresma Patel, Djelila Mezaache, Rakhi Shah, Anamitro Banerjee, Sherita McLamore, Adam N. Maung, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, R. Angelo De Claro
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2488–2492.
https://doi.org/10.1158/1078-0432.CCR-21-4176
Published: 13 June 2022
View article titled, FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Open the PDF for FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

Ruo-Jing Li, Runyan Jin, Chao Liu, Xianhua Cao, Michael L. Manning, Xu Michael Di, Donna Przepiorka, Frances Namuswe, Albert Deisseroth, Kirsten B. Goldberg, Gideon M. Blumenthal, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 328–331.
https://doi.org/10.1158/1078-0432.CCR-19-1255
Published: 15 January 2020
View article titled, FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults
Open the PDF for FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults in another window
Includes: Supplementary data
Journal Articles

Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole

Joong Sup Shim, Ruo-Jing Li, Namandje N. Bumpus, Sarah A. Head, Kalyan Kumar Pasunooti, Eun Ju Yang, Junfang Lv, Wei Shi, Jun O. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2709–2720.
https://doi.org/10.1158/1078-0432.CCR-15-1888
Published: 31 May 2016
View article titled, Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole
Open the PDF for Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole in another window
Includes: Supplementary data